Elite Pharmaceuticals Inc. (ELTP) Financials Nov 14, 2014,

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
Elite Pharmaceuticals Inc. (ELTP) Financials Nov 14, 2014, 3:58 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Elite Pharmaceuticals Inc.


Fiscal year is April-March. All values USD millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 3.34M 4.27M 2.42M 3.4M 4.6M
Cost of Goods Sold (COGS) incl. D&A 2.52M 2.85M 1.22M 2.43M 3.74M
COGS excluding D&A 2.01M 2.37M 735,771 2.01M 3.24M
Depreciation & Amortization Expense 508,610 483,473 484,151 423,340 500,906
Depreciation - - 484,151 423,340 486,726
Amortization of Intangibles - - 0 0 14,180
Gross Income 824,541 1.42M 1.2M 971,451 864,364
2010 2011 2012 2013 2014 5-year trend
SG&A Expense 2.76M 2.3M 3.17M 2.53M 6.15M
Research & Development 794,433 1.39M 1.74M 975,250 3.96M
Other SG&A 1.97M 918,030 1.43M 1.56M 2.19M
Other Operating Expense 0 0 0 0 0
Unusual Expense 4.08M 11.21M 12.67M (3.53M) 90.7M
EBIT after Unusual Expense (4.08M) (11.21M) (12.67M) 3.53M (90.7M)
Non Operating Income/Expense (512,912) (292,213) (249,999) (437,500) 19,831
Non-Operating Interest Income 1,064 - 0 0 0
Equity in Affiliates (Pretax) 0 0 - - -
Interest Expense 1.53M 1.49M 654,057 392,964 899,916
Gross Interest Expense 1.53M 1.49M 654,057 392,964 899,916
Interest Capitalized 0 0 - - 0
Pretax Income (8.06M) (13.88M) (15.54M) 1.13M (96.87M)
Income Tax 0 (301,413) (483,952) (353,718) (292,611)
Income Tax - Current Domestic 0 - (483,952) (353,718) (292,611)
Income Tax - Current Foreign 0 0 - - -
Income Tax - Deferred Domestic 0 0 0 0 0
Income Tax - Deferred Foreign 0 0 - - -
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) - 0 (109,015) 0 0
Consolidated Net Income (8.06M) (13.58M) (15.17M) 1.49M (96.58M)
Minority Interest Expense 0 0 0 0 0
Net Income (8.06M) (13.58M) (15.17M) 1.49M (96.58M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - - 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (8.06M) (13.58M) (15.17M) 1.49M (96.58M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (8.06M) (13.58M) (15.17M) 1.49M (96.58M)
EPS (Basic) (0.11) (0.14) (0.06) 0.00 (0.21)
Basic Shares Outstanding 75.58M 100.02M 259.16M 349.08M 463.02M
EPS (Diluted) (0.11) (0.14) (0.06) () (0.21)
Diluted Shares Outstanding 75.58M 100.02M 259.16M 526.88M 463.02M
EBITDA (1.43M) (402,287) (1.48M) (1.14M) (4.78M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 7

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 6

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 8

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 8

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 11

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 12

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 5

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 12

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 11

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading

Top 5 Most Recently Viewed Articles

A Closer Look at Marvell Tech's Upcoming Earnings Release

Updated Category News Views 184

Marvell Tech's Expected Earnings Release Marvell Tech (NASDAQ: MRVL) is set to announce its latest quarterly earnings in December. As investors await this critical financial moment, a brief review of what to expect can shed light on potential impacts and opportunities. Analysts' Earnings Projections Analysts forecast that Marvell Tech will achieve an earnings per share...

Continue Reading
Banijay Group's Recent Share Transactions Update and Insights

Updated Category News Views 222

Recent Share Transactions Overview Banijay Group N.V. (ISIN: NL0015000X07, Bloomberg: BNJ NA, Reuters: BNJ.AS) has reported on its recent share transactions, showcasing the buying and selling activities from the period of September 22 to September 26. Understanding Share Transactions During this timeframe, a mix of buying and selling occurred within the company’s...

Continue Reading
Strategic Growth for Voyageur Mineral Explorers via New Offering

Updated Category News Views 143

Voyageur Mineral Explorers Corp. Secures Massive Funding Voyageur Mineral Explorers Corp. (CSE: VOY) has recently made headlines by completing a significant brokered offering, raising $37.5 million. This financial boost comes at a crucial time for the Company as it seeks to expand its operations and investments in the mineral exploration sector. The offering was executed...

Continue Reading
Applied Materials Faces Challenges Amid Weak Outlook and Stocks

Updated Category News Views 114

Applied Materials Inc. Stock Performance Applied Materials Inc. (NASDAQ: AMAT) recently experienced a noticeable decline in its stock value as the company shared its financial results. After the market closure, the organization revealed its third-quarter earnings, leading to significant concern among investors. The stock's value tumbled, reflecting the market's reaction...

Continue Reading
VFC Class Action Demands Attention: Key Details for Investors

Updated Category News Views 192

Understanding the VFC Class Action Lawsuit Investors in V.F. Corporation, commonly known as VFC, should pay close attention to a pending class action lawsuit that could have significant implications. The law firm Faruqi & Faruqi, a reputable name in securities litigation, has stepped forward to represent affected investors. They are drawing attention to a critical...

Continue Reading